A Phase 4 interventional study of Maraviroc and Maraviroc in Human Immunodeficiency Virus (HIV) Infection, sponsored by ViiV Healthcare. Completed at 2 sites in Germany. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2010-11-19.
Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to assess whether a dosing adjustment is needed in patients with renal impairment.
3,038 studies on the registry are indexed under Acquired Immunodeficiency Syndrome; 308 are open to participants now.
This study's enrollment of 30 is below the median of 96 across 2,253 interventional studies indexed under Acquired Immunodeficiency Syndrome.
Browse Acquired Immunodeficiency Syndrome studies →ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.
Compared within Acquired Immunodeficiency Syndrome, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects with Normal Renal Function (Creatinine Clearance \> 80mL/min) (I) Maraviroc single dose, followed by (II) Maraviroc + Saquinavir/Ritonavir
Drug: Maraviroc · Drug: Ritonavir · Drug: Saquinavir
Subjects with Mild Renal Impairment (Creatinine Clearance \>50 and ≤80 mL/min)
Drug: Maraviroc · Drug: Ritonavir · Drug: Saquinavir
Subjects with Moderate Renal Impairment (Creatinine Clearance ≥30 and ≤50 mL/min)
Drug: Maraviroc · Drug: Ritonavir · Drug: Saquinavir
Subjects with Severe Renal Impairment (Creatinine Clearance \<30 mL/min)
Drug: Maraviroc
Subjects with End Stage Renal Impairment receiving Hemodialysis(Creatinine Clearance \<30 mL/min) (I) Maraviroc single dose one hour following completion of hemodialysis, followed by (II) Maraviroc single dose three hours prior to start of hemodialysis
Drug: Maraviroc
Maraviroc 300 mg (150 mg x 2 tablets) x single dose
Maraviroc 150 mg tablet twice daily x 7 days
Ritonavir 100 mg capsule twice daily x 7 days
Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
Maraviroc 150 mg tablet once daily x 7 days
Ritonavir 100 mg capsule twice daily x 7 days
Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
Maraviroc 150 mg tablet once every 48 hours x 7 days
Ritonavir 100 mg capsule twice daily x 7 days
Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
Maraviroc 300 mg (150 mg x 2 tablets) x single dose
Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis
Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis
Area Under the Plasma Concentration Time-curve From Zero to the Last Measured Concentration (AUClast)
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) measured in nanograms \* hour divided by milliliters (ng\*hr/mL).
Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
AUCtau
AUCtau: area under the plasma concentration-time profile from time zero to the end of the dosing interval (tau); measured in nanograms \* hours divided by milliliters (ng.hr/mL).
Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Maximum Observed Plasma Concentration (Cmax)
Maximum observed plasma concentration (Cmax) within the dosing interval; measured in nanograms per milliliter (ng/mL).
Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Plasma Protein Binding
Percent protein binding (protein unbound maraviroc (MVC) fraction \[percent free\]) was determined by rapid equilibrium dialysis. Percent free = 100 - percent bound.
Time frame: 2 hours post-dose; normal Day -3 and Day 7; mild moderate: Day 7; severe and ESRD: Day 1
Area Under the Time Curve From 0 to Infinity (AUCinf)
Area under the plasma concentration-time profile from time zero to the time infinate in subjects who received single dose treatment; measured in nanograms \* hour divided by millilters (ng\*hr/mL).
Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72
Time of First Occurrence (Tmax)
Time (hours) of first occurrence (Tmax); time after dosing when Cmax (maximum plasma concentration) occured.
Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Half-life (t1/2)
Elimination half-life (t1/2) measured in hours: time required for half the quantity of maraviroc to be metabolized or eliminated by normal biological processes.
Time frame: Pre-dose, post-dose hours 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Renal Clearance (CLR) in Subjects With Normal, Mild, Moderate and Severe Renal Function
Renal clearance (CLR) measured in milliliters per minute (mL/min).
Time frame: Hour 0 (prior to MVC dosing [single dose] or prior to last MVC dose [multiple dose]) to 72 hours post-dose ; hours 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Derivation of Renal Clearance in Subjects With Normal, Mild, Moderate and Severe Renal Function: Ae
Ae: amount of drug excreted unchanged in the urine; measured in milligrams (mg).
Time frame: Hour 0 (prior to MVC dosing [single dose] or prior to last MVC dose [multiple dose]) to 72 hours post-dose ; hours 0, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72.
Hemodialysis Clearance of Maraviroc (MVC) in Subjects With End Stage Renal Disease (ESRD) Undergoing Hemodialysis: CLdD
CLdD: dialysate clearance before dialysis; measured in milliliters per minute.
Time frame: Before dialysis
Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Maximum Increase and Decrease in Supine Blood Pressure
Number of subjects with absolute values of supine systolic blood pressure (BP) measured in millimeters of mercury (mm/Hg), range: \<90 mmHg; and supine diastolic blood pressure, range: \<50 mmHg. Number of subjects with a maximum increase and decrease from Baseline in supine systolic BP ≥ 30 mmHg. Number of subjects with a maximum increase and decrease from Baseline in supine diastolic BP ≥ 20 mmHg.
Time frame: Normal renal function: screening, Day -3 to Day -1; normal, mild and moderate RI: Day 7 to Day 10 and follow-up; severe RI: Day 1 to Day 4 and follow-up; ESRD: Day 1, Day 4, and follow-up
Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Pulse Rate < 40 and > 120 Beats Per Minute
Number of subjects with pulse rate \< 40 beats per minute (BPM), number of subjects with pulse rate \> 120 BPM.
Time frame: Normal renal function: screening, Day -3 to Day -1; normal, mild and moderate RI: Day 7 to Day 10 and follow-up; severe RI: Day 1 to Day 4 and follow-up; ESRD: Day 1, Day 4, and follow-up
Safety and Tolerability of Maraviroc in the Absence and Presence of a Potent CYP3A4 Inhibitor in Subjects With Various Degrees of Renal Impairment or Undergoing Hemodialysis: Number of Subjects With Maximum EGC QTC, QTCB and QTCF Intervals
Single 12-lead ECG: number of subjects with maximum QTC interval, maximum QTCB interval (Bazett's correction), and maximum QTCF interval (Friderica's correction) measured in milliseconds (msec); range: 450 to \<480 msec, 480 to \<500 msec, and \>500 msec. Maximum QTC interval increase from Baseline; citeria: change = ≥ 30 msec to \< 60 msec, and change = ≥ 60 msec.
Time frame: Normal renal function: screening, Day -3 and Day -1; normal renal function, mild and moderate RI: Day 7 to Day 9 and follow-up; severe RI: screening, Day 1, Day 3, Day 4, and follow-up; ESRD: screening, Day 1, Day 3, Day 4, and follow-up
Two centers took part in this study between 15 July 2008 and 21 November 2008.
| Milestone | Healthy Subjects | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | ESRD: Single Dose |
|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 0 | 0 |
| Completed | 6 | 6 | 5 | 0 | 0 |
| Not completed | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 0 | 0 |
| Milestone | Healthy Subjects | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | ESRD: Single Dose |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 6 | 0 |
| Completed | 0 | 0 | 0 | 6 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Healthy Subjects | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | ESRD: Single Dose |
|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 6 |
| Completed | 0 | 0 | 0 | 0 | 6 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) measured in nanograms \* hour divided by milliliters (ng\*hr/mL).
| ng*hr/mL | Healthy Subjects: Multiple Dose | Mild Renal Impairment: Multiple Dose | Moderate Renal Impairment: Multiple Dose | Healthy Subjects: Single Dose | Severe Renal Impairment: Single Dose | ESRD: Single Dose; After Dialysis | ESRD: Single Dose; Before Dialysis |
|---|---|---|---|---|---|---|---|
| Area Under the Plasma Concentration Time-curve From Zero to the Last Measured Concentration (AUClast) | 7356.3 ± 2313.45 | 9502.1 ± 3599.32 | 6496.0 ± 1795.89 | 1320.7 ± 988.66 | 4255.5 ± 2424.19 | 2636.5 ± 1123.34 | 2770.1 ± 1356.56 |
AUCtau: area under the plasma concentration-time profile from time zero to the end of the dosing interval (tau); measured in nanograms \* hours divided by milliliters (ng.hr/mL).
| ng*hr/mL | Healthy Subjects: Multiple Dose | Mild Renal Impairment: Multiple Dose | Moderate Renal Impairment: Multiple Dose |
|---|---|---|---|
| AUCtau | 5341.4 ± 1498.27 | 8118.7 ± 2995.27 | 6193.3 ± 1762.41 |
Maximum observed plasma concentration (Cmax) within the dosing interval; measured in nanograms per milliliter (ng/mL).
| ng/mL | Healthy Subjects: Multiple Dose | Mild Renal Impairment: Multiple Dose | Moderate Renal Impairment: Multiple Dose | Healthy Subjects: Single Dose | Severe Renal Impairment: Single Dose | ESRD: Single Dose; After Dialysis | ESRD: Single Dose; Before Dialysis |
|---|---|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 950.91 ± 220.368 | 1150.74 ± 392.167 | 674.20 ± 275.722 | 335.60 ± 393.024 | 801.16 ± 525.656 | 576.7 ± 339.27 | 478.5 ± 198.81 |
Percent protein binding (protein unbound maraviroc (MVC) fraction \[percent free\]) was determined by rapid equilibrium dialysis. Percent free = 100 - percent bound.
| percent free | Healthy Subjects: Multiple Dose | Mild Renal Impairment: Multiple Dose | Moderate Renal Impairment: Multiple Dose | Healthy Subjects: Single Dose | Severe Renal Impairment: Single Dose | ESRD |
|---|---|---|---|---|---|---|
| minimum protein unbound MVC fraction | 19.7 (14.6 to 28.2) | 15.3 (15.3 to 29.1) | 18.1 (18.1 to 31.6) | 14.6 (19.2 to 28.1) | 19.2 (18.2 to 27.8) | 18.2 (18.2 to 27.8) |
| maximum protein unbound MVC fraction | 26.6 | 29.1 | 31.6 | 28.2 | 28.1 | 27.8 |
Area under the plasma concentration-time profile from time zero to the time infinate in subjects who received single dose treatment; measured in nanograms \* hour divided by millilters (ng\*hr/mL).
| ng*hr/mL | Healthy Subjects: Single Dose | Severe Renal Impairment: Single Dose | ESRD: Single Dose; After Dialysis | ESRD: Single Dose; Before Dialysis |
|---|---|---|---|---|
| Area Under the Time Curve From 0 to Infinity (AUCinf) | 1348.4 ± 986.65 | 4367.7 ± 2518.78 | 2677.4 ± 1149.85 | 2805.5 ± 1374.71 |
Time (hours) of first occurrence (Tmax); time after dosing when Cmax (maximum plasma concentration) occured.
| hours | Healthy Subjects: Multiple Dose | Mild Renal Impairment: Multiple Dose | Moderate Renal Impairment: Multiple Dose | Healthy Subjects: Single Dose | Severe Renal Impairment: Single Dose | ESRD: Single Dose; After Dialysis | ESRD: Single Dose; Before Dialysis |
|---|---|---|---|---|---|---|---|
| Time of First Occurrence (Tmax) | 1.000 (0.50 to 2.00) | 1.500 (0.50 to 4.00) | 2.000 (0.50 to 4.02) | 2.500 (0.50 to 4.02) | 2.500 (0.50 to 4.00) | 3.000 (1.00 to 4.00) | 2.000 (0.50 to 4.17) |
Elimination half-life (t1/2) measured in hours: time required for half the quantity of maraviroc to be metabolized or eliminated by normal biological processes.
| hour | Healthy Subjects: Multiple Dose | Mild Renal Impairment: Multiple Dose | Moderate Renal Impairment: Multiple Dose | Healthy Subjects: Single Dose | Severe Renal Impairment: Single Dose | ESRD: Single Dose; After Dialysis | ESRD: Single Dose; Before Dialysis |
|---|---|---|---|---|---|---|---|
| Half-life (t1/2) | 14.22 ± 1.166 | 16.84 ± 5.568 | 16.99 ± 3.141 | 14.36 ± 4.030 | 17.29 ± 4.171 | 15.03 ± 3.329 | 13.86 ± 1.051 |
Renal clearance (CLR) measured in milliliters per minute (mL/min).
| mL/min | Healthy Subjects: Multiple Dose | Mild Renal Impairment: Multiple Dose | Moderate Renal Impairment: Multiple Dose | Healthy Subjects: Single Dose | Severe Renal Impairment: Single Dose |
|---|---|---|---|---|---|
| Renal Clearance (CLR) in Subjects With Normal, Mild, Moderate and Severe Renal Function | 105.7 ± 56.00 | 77.2 ± 36.71 | 62.5 ± 12.57 | 110.0 ± 38.67 | 26.6 ± 18.84 |
Ae: amount of drug excreted unchanged in the urine; measured in milligrams (mg).
| mg | Healthy Subjects: Multiple Dose | Mild Renal Impairment: Multiple Dose | Moderate Renal Impairment: Multiple Dose | Healthy Subjects: Single Dose | Severe Renal Impairment: Single Dose |
|---|---|---|---|---|---|
| Derivation of Renal Clearance in Subjects With Normal, Mild, Moderate and Severe Renal Function: Ae | 41.6 ± 22.45 | 39.1 ± 11.23 | 24.9 ± 8.88 | 10.8 ± 7.41 | 8.4 ± 6.35 |
CLdD: dialysate clearance before dialysis; measured in milliliters per minute.
| mL/min | ESRD: Single Dose; Before Dialysis |
|---|---|
| Hemodialysis Clearance of Maraviroc (MVC) in Subjects With End Stage Renal Disease (ESRD) Undergoing Hemodialysis: CLdD | 36.42 ± 12.710 |
Number of subjects with absolute values of supine systolic blood pressure (BP) measured in millimeters of mercury (mm/Hg), range: \<90 mmHg; and supine diastolic blood pressure, range: \<50 mmHg. Number of subjects with a maximum increase and decrease from Baseline in supine systolic BP ≥ 30 mmHg. Number of subjects with a maximum increase and decrease from Baseline in supine diastolic BP ≥ 20 mmHg.
| subjects | Healthy Subjects: Multiple Dose | Mild Renal Impairment: Multiple Dose | Moderate Renal Impairment: Multiple Dose | Healthy Subjects: Single Dose | Severe Renal Impairment: Single Dose | ESRD: Single Dose; After Dialysis | ESRD: Single Dose; Before Dialysis |
|---|---|---|---|---|---|---|---|
| BL Supine Systolic Blood Pressure (BP) <90 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maximum Increase from BL: Supine Systolic BP≥ 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maximum Decrease from BL: Supine Systolic BP ≥ 30 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| BL Supine Diastolic Blood Pressure (BP) <50 mmHg | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maximum Increase from BL: Supine Diastolic BP≥ 20 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Maximun Decrease from BL: Supine Diastolic BP ≥20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number of subjects with pulse rate \< 40 beats per minute (BPM), number of subjects with pulse rate \> 120 BPM.
| bpm | Healthy Subjects: Multiple Dose | Mild Renal Impairment: Multiple Dose | Moderate Renal Impairment: Multiple Dose | Healthy Subjects: Single Dose | Severe Renal Impairment: Single Dose | ESRD: Single Dose; After Dialysis | ESRD: Single Dose; Before Dialysis |
|---|---|---|---|---|---|---|---|
| Supine Pulse Rate <40 BPM | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Supine Pulse Rate >120 BPM | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Single 12-lead ECG: number of subjects with maximum QTC interval, maximum QTCB interval (Bazett's correction), and maximum QTCF interval (Friderica's correction) measured in milliseconds (msec); range: 450 to \<480 msec, 480 to \<500 msec, and \>500 msec. Maximum QTC interval increase from Baseline; citeria: change = ≥ 30 msec to \< 60 msec, and change = ≥ 60 msec.
| subjects | Healthy Subjects: Multiple Dose | Mild Renal Impairment: Multiple Dose | Moderate Renal Impairment: Multiple Dose | Healthy Subjects: Single Dose | Severe Renal Impairment: Single Dose | ESRD: Single Dose; After Dialysis | ESRD: Single Dose; Before Dialysis |
|---|---|---|---|---|---|---|---|
| Maximum QTC Interval: 450 to < 480 msec | 1 | 0 | 0 | 1 | 2 | 1 | 0 |
| Maximum QTC Interval: 480 to < 500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maximum QTC Interval: > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maximum QTCB Interval: 450 to < 480 msec | 1 | 0 | 0 | 1 | 1 | 0 | 0 |
| Maximum QTCB Interval: 480 to < 500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maximum QTCB Interval: > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maximum QTCF Interval: 450 to 480 msec | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Maximum QTCF Interval: 480 to < 500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Maximum QTCF Interval: > 500 msec | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Max. QTC Interval Increase from BL: change ≥30 <60 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| QTC Interval Increase from BL: change ≥ 60 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Subjects | — | 0/6 (0%) | 2/6 (33.3%) |
| Mild Renal Impairment | — | 0/6 (0%) | 6/6 (100%) |
| Moderate Renal Impairment | — | 0/6 (0%) | 6/6 (100%) |
| Healthy Subjects: Single Dose | — | 0/6 (0%) | 1/6 (16.7%) |
| Severe Renal Impairment: | — | 0/6 (0%) | 3/6 (50%) |
| ESRD: Dosing After Dialysis | — | 0/6 (0%) | 2/6 (33.3%) |
| ESRD: Dosing Before Dialysis | — | 0/6 (0%) | 1/6 (16.7%) |
| Event | Healthy Subjects | Mild Renal Impairment | Moderate Renal Impairment | Healthy Subjects: Single Dose | Severe Renal Impairment: | ESRD: Dosing After Dialysis | ESRD: Dosing Before Dialysis |
|---|---|---|---|---|---|---|---|
| blood creatinine increasedInvestigations | 0/6 | 4/6 | 4/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| blood urea increasedInvestigations | 0/6 | 3/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| headacheNervous system disorders | 2/6 | 3/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| nocturiaRenal and urinary disorders | 0/6 | 3/6 | 3/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| flatulenceGastrointestinal disorders | 2/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 |
| fatigueGeneral disorders | 0/6 | 2/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| conjunctival hyperaemiaEye disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| visual impairmentEye disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| abdominal distensionGastrointestinal disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| abdominal pain upperGastrointestinal disorders | 1/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 |
| Age, Customized(years) | Healthy Subjects | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | ESRD on Hemodialysis | Total |
|---|---|---|---|---|---|---|
| 18 - 44 years | 0 | 0 | 1 | 1 | 1 | 3 |
| 45 - 64 years | 5 | 4 | 0 | 2 | 4 | 15 |
| >= 65 years | 1 | 2 | 5 | 3 | 1 | 12 |
| Sex: Female, Male(Participants) | Healthy Subjects | Mild Renal Impairment | Moderate Renal Impairment | Severe Renal Impairment | ESRD on Hemodialysis | Total |
|---|---|---|---|---|---|---|
| Female | 2 | 2 | 2 | 2 | 0 | 8 |
| Male | 4 | 4 | 4 | 4 | 6 | 22 |
The record gives a start of Jul 2008, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maraviroc
Acquired Immunodeficiency Syndrome →